This content is machine translated Uncontrolled type 2 diabetes Empagliflozin as an effective addition to triple therapies In patients with type 2 diabetes (T2D), a balanced glucose concentration is mainly achieved through drug therapies. If blood glucose control remains poor despite a triple combination of oral hypoglycaemic...…
View Post 4 min This content is machine translated Type 2 diabetes, high blood pressure and cardiovascular risk SGLT2 inhibitors are also a matter of the heart There are up to six SGLT isoforms, whereby SGLT2 has come into particular focus in recent years due to its importance for type 2 diabetes mellitus. SGLT2 inhibitors lower blood…
View Post 4 min This content is machine translated Renal effects of empagliflozin Combination with semaglutide does not reduce albuminuria more than Empa mono SGLT2 inhibitors and GLP1 receptor agonists (GLP1-RA) are antidiabetic drugs with the potential to preserve kidney function. Their different mechanisms of action suggest that combination therapy could have additive or…
View Post 4 min This content is machine translated SGLT-2-i in type 2 diabetes and CVD Cardioprotective mechanisms of action of empagliflozin – what’s new? Empagliflozin is known to reduce the risk of atherosclerotic cardiovascular disease (CVD) in people with type 2 diabetes and high cardiovascular risk. The mechanisms underlying these effects are not yet…
View Post 4 min This content is machine translated Heart failure: ESC guideline update 2023 Treatment of HFmrEF – what’s new? The European Society of Cardiology (ESC) recently updated its guidelines. Consequently, based on the EMPEROR-Preserved and DELIVER trials, the use of SGLT-2 inhibitors is now recommended for all stages of…
View Post 5 min This content is machine translated Heart failure in type 2 diabetes Success story of SGLT-2 inhibitors – impressive evidence base. The SGLT(“sodium glucose-linked transporter”)-2 inhibitors have demonstrated cardioprotective effects in addition to antidiabetic effects. The current evidence supports the benefit of several agents of SGLT-2-i in the treatment of heart…
View Post 5 min This content is machine translated Heart failure Pharmacotherapy in HFrEF and HFmrEF – Combination of four as gold standard. Important therapeutic goals in chronic heart failure are to improve quality of life and to reduce the risk of hospitalization and mortality. According to current evidence, guideline-based therapy with the…
View Post 4 min This content is machine translated European Diabetes Congress in Stockholm First antidiabetic drug with proven reduction in cardiovascular risk Some 15,600 people from 134 countries attended the 51st European Diabetes Conference in Stockholm (Annual Meeting of the European Association for the Study of Diabetes). The results of the EMPA-REG…
